Physician profile
David S Weiland
NPI 1659384121
$9,794.54
in general payments reported to CMS, 2019-2025
39 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $665 · 2021: $1,982 · 2022: $2,405 · 2023: $2,103 · 2024: $449 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,822.90 | 2021-2023 | Advisa Dr Mri Surescan, Adapta, Onyx Frontier |
| Boehringer Ingelheim Pharmaceuticals, INC. | $952.76 | 2019-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $802.08 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $666.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $602.26 | 2019-2024 | |
| Abiomed | $504.49 | 2019-2022 | |
| Amgen INC. | $414.54 | 2019-2023 | Repatha |
| Philips North America LLC | $402.92 | 2023-2025 | (Br1) Coronary Specialty Balloon, Omniwire, (6585) Omniwire |
| Astrazeneca Pharmaceuticals LP | $396.41 | 2019-2022 | |
| Abbott Laboratories | $377.66 | 2020-2024 | Dragonfly Opstar, Ensite Precision, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $369.03 | 2019-2023 | Camzyos, Eliquis |
| Pfizer INC. | $340.68 | 2019-2021 | |
| Boston Scientific Corporation | $322.18 | 2019-2023 | Bodyguardian, Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $245.51 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $175.68 | 2022-2023 | Verquvo, Belsomra, Lagevrio |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $156.36 | 2019-2023 | |
| Esperion Therapeutics, INC. | $135.23 | 2021-2023 | Nexletol |
| Shockwave Medical, INC | $129.96 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $120.58 | 2022-2023 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $87.31 | 2023 | Arcalyst |
| Cathworks, INC. | $87.23 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.96 | 2022-2023 | |
| Biotronik INC. | $70.19 | 2019-2021 | |
| Amarin Pharma, INC. | $61.90 | 2020 | |
| Novo Nordisk INC | $61.21 | 2021-2023 | Ozempic, Rybelsus |
| Bardy Diagnostics, INC. | $60.58 | 2021 | |
| Baxter Healthcare | $57.80 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Inari Medical, INC. | $37.56 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $28.21 | 2022 | |
| Atricure, INC. | $27.97 | 2023 | |
| Terumo Medical Corporation | $27.47 | 2021-2022 | |
| Heartflow, INC. | $27.22 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $26.12 | 2023 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $23.19 | 2023 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $22.98 | 2022 | |
| Irhythm Technologies, INC. | $21.06 | 2019 | |
| Daiichi Sankyo INC. | $17.14 | 2023 | Injectafer |
| Penumbra, INC. | $15.78 | 2020 | |
| Asahi Intecc USA, INC. | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weiland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.